May 31, 2023
Aravax doses first patient in Phase 2 peanut allergy clinical trials
1 June, Melbourne, Australia: The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax,...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page